In this article we will take a look at some of the top stocks picks of Cathie Wood from the sectors she is bullish on. To read our detailed analysis of ARK’s performance and Cathie Wood’s latest comments on the market, go to Cathie Wood’s Strong Comeback: ARK’s Latest Stock Picks, Portfolio Updates and Comments
5. Twist Bioscience Corporation (NASDAQ: TWST)
Twist Bioscience makes synthetic DNA for clients in the biotechnology industry. It is also known for an advanced liquid handling robot technology that builds DNA in the microplates. In March, the FDA approved the company’s SARS-CoV-2 next-generation sequencing assay. The assay can analyze the entire RNA viral sequence and generate reports to analyze RNA sequence to detect genetic variants and lineages of SARS-CoV-2.
As of the end of the fourth quarter of 2020, ARK Investment Management owns 5.9 million shares of TWST worth $830.4 million. TWST accounts for 2.2% of ARK’s total portfolio.
4. Square, Inc. (NYSE: SQ)
Square is another payments company getting some love from Cathie Wood. The stock was recently upgraded by KBW analyst Sanjay Sakhrani to Outperform from Market Perform. The analyst believes that the company is a “long-term” winner in an “undeserved” market. The analyst especially likes the company’s Seller and Cash App systems. The analyst set a price target of $250 for the stock.
ARK Investment Management currently owns 7.08 million shares of Square, worth $1.54 billion. SQ occupies 4.1% of ARK’s overall equity.
3. Teladoc Health, Inc. (NYSE: TDOC)
Teladoc is one of the most popular telehealth companies in the U.S., with over 52 million paying members. The company has a network of over 50,000 licensed physicians globally, and saw huge growth in 2020 as people started using its platform to seek medical treatment during stay-at-home orders. Teladoc added 15 million members in 2020.
ARK Investment Management currently holds 7.8 million shares of TDOC that amounts $1.6 billion. TDOC occupies 4.16% of ARK’s total portfolio.
2. CRISPR Therapeutics AG (NASDAQ: CRSP)
One of the most notable names in gene editing and DNA sequencing, CRISPR is known for its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform which allows changes to genomic deoxyribonucleic acid (DNA). FDA recently approved the company’s experimental treatment for clinical trials. This would allow the first human tests of a CRISPR-based therapy to directly correct the mutation in the beta-globin gene responsible for sickle cell disease. The tests would take four years before they yield meaningful results.
As of the end of the fourth quarter of 2020, ARK Investment Management owns 10.4 million shares of CRSP worth $1.6 billion. CRSP accounts for 4.24% of ARK’s total portfolio.
1. Tesla, Inc. (NASDAQ:TSLA)
Cathie Wood’s trust in Tesla remains unwavering as several other analysts are beginning to question the company’s hype and valuation. Cathie Wood recently caused a stir after giving a $3000 price target for Tesla. Tesla shares have gained 640% over the last 12 months. A total of 68 hedge funds out of 887 tracked by Insider Monkey held long positions in Tesla, as of the end of the fourth quarter of 2020.
Cathie Wood’s ARK Investment Management currently holds 4.1 million shares of Tesla, worth $2.92 billion. TSLA occupies 7.76% of ARK’s total portfolio.
You can also take a peek at Cathie Wood’s Thoughts on the Future, ARK’s Portfolio, and Latest Stock Picks and Cathie Wood’s Top 10 Stock Picks.